Teclistamab delivers deeper responses in relapsed myeloma patients

https://www.news-medical.net/news/20260529/Teclistamab-delivers-deeper-responses-in-relapsed-myeloma-patients.aspx Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.